GlassScriptPhysician profile
Richard T Shaffer
NPI 1134158736
$6,323.15
in general payments reported to CMS, 2019-2025
33 companies · $39.28 in 2025
The $39.28 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $256 · 2021: $997 · 2022: $1,123 · 2023: $1,644 · 2024: $1,532 · 2025: $39.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,131 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,130.75 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,920.71 | 2019-2024 | Skyrizi, Rinvoq, Mavyret |
| Janssen Biotech, INC. | $732.21 | 2019-2024 | Stelara, Simponi, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $649.56 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $452.97 | 2019-2024 | |
| Celgene Corporation | $402.76 | 2021-2024 | Zeposia |
| Genzyme Corporation | $248.63 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $247.34 | 2019-2022 | |
| Gilead Sciences, INC. | $238.45 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $152.61 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $144.40 | 2022-2024 | Dupixent |
| Ardelyx, INC. | $125.24 | 2022-2024 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $116.74 | 2022-2023 | |
| Lilly USA, LLC | $89.34 | 2024 | Omvoh |
| Shire North American Group INC | $80.83 | 2019 | |
| Amag Pharmaceuticals, INC. | $79.38 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $75.77 | 2019-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $73.08 | 2020-2024 | Linzess |
| Redhill Biopharma INC. | $67.84 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Ucb, INC. | $49.96 | 2019 | |
| Aimmune Therapeutics, INC. | $48.78 | 2024-2025 | Vowst |
| Qol Medical, LLC | $47.38 | 2019-2024 | Sucraid |
| Celltrion USA INC. | $47.03 | 2024 | Vegzelma |
| Horizon Therapeutics Plc | $40.16 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $39.86 | 2024 | Iqirvo |
| Evoke Pharma, INC. | $29.74 | 2024 | |
| Braintree Laboratories, INC. | $24.75 | 2023 | Suflave, Sutab |
| Merck Sharp & Dohme LLC | $23.23 | 2024 | Dificid |
| Olympus America INC. | $18.83 | 2021 | |
| Sandoz INC. | $18.73 | 2023 | Hyrimoz |
| Daiichi Sankyo INC. | $18.68 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.63 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $5.53 | 2024 | Forceps |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$84,822.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.